One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
bluebird bio logo
bluebird bio BLUE
report update icon

Quarterly report 2025-Q1
added 05-16-2026

bluebird bio Financial Ratios 2024-2010 | BLUE

Annual Financial Ratios bluebird bio

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

P/E

- -0.0 -1.5 -0.5 -2.0 -5.7 -12.2 -26.4 -9.7 -8.6 -50.6 -11.1 - - -

P/S

- 0.1 98.5 113.7 5.0 101.6 124.1 250.4 415.5 101.8 97.0 13.9 - - -

EPS

-24.8 -38.6 -2.9 -11.9 -9.9 -14.3 -10.7 -7.7 -7.1 -4.8 -1.8 -2.0 -13.8 -171.6 -

EV (Enterprise Value)

429 M 206 M 677 M 475 M 1.3 B 4.65 B 6.73 B 8.39 B 2.53 B 1.42 B 2.18 B 147 M 58.1 M 61 M -9.35 M

EBITDA per Share

-21.7 -39.4 -3.08 -8.5 -8.91 -14.4 -10.6 -7.33 -6.82 -4.58 -2.12 -1.91 - - -

EV/EBITDA

-2.0 -1.0 -2.8 -0.8 -3.6 -5.3 -11.5 -25.4 -9.0 -8.0 -37.7 -3.1 - - -

PEG

- -0.0 0.3 -0.06 -0.1 0.17 0.32 2.92 0.21 0.05 -5.38 0.12 - - -

P/B

- 0.0 2.6 1.1 0.9 3.5 3.6 5.5 2.9 1.7 5.0 1.8 - - -

P/CF

- -0.0 -1.1 -0.7 -2.7 -7.1 -14.4 -25.9 -12.4 -13.6 -36.1 8.1 - - -

ROE %

763.35 -108.93 -171.47 -218.92 -45.66 -61.45 -29.48 -20.67 -30.31 -19.61 -9.92 -16.70 - - -

ROA %

-52.30 -34.23 -40.42 -137.99 -34.73 -45.71 -24.77 -17.66 -23.57 -16.64 -8.75 -11.28 - - -

ROCE %

857.68 -125.56 -186.24 -157.88 -41.27 -54.00 -27.14 -18.43 -25.27 -17.27 -11.75 -13.16 - - -

Current Ratio

0.9 1.5 1.3 2.7 4.2 5.2 9.7 13.8 9.7 13.0 11.2 6.1 - - -

DSO

0.7 2.5 20.3 169.4 2.3 104.8 93.2 32.1 - - - - - - -

DIO

179.6 124.8 - - - - - - - - - - - - -

DPO

107.8 181.6 738.0 - - 5269.7 7354.0 3077.0 - - - - - - -

Operating Cycle

180.2 127.2 20.3 169.4 2.3 104.8 93.2 32.1 - - - - - - -

Cash Conversion Cycle

72.4 -54.4 -717.7 169.4 2.3 -5164.9 -7260.9 -3045.0 - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios bluebird bio

2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-2.98 - -0.31 -0.42 -7.23 - -0.8 -0.58 0.18 - -0.94 -1.36 -1.66 -2.14 -3.16 -3.58 -3.07 -3.01 -2.94 -0.36 -3.64 -4.04 -3.73 -3.55 -2.99 -2.72 -2.73 -2.91 -2.31 -2.52 -1.73 -1.73 -1.68 -1.88 -2.07 -1.59 -1.52 -1.29 -1.18 -1.57 -0.76 -0.67 -0.61 -0.06 -0.44 -0.34 -0.26 -2.13 -19.94 -12.5 1.15 -23.21 -28.49 - - - -

EBITDA per Share

-0.93 - - - -6.55 - - - 0.16 - -0.99 -1.46 -1.62 -1.91 -2 -2.29 -2.1 -2.1 -1.77 -2.22 -2.51 -4.16 -3.58 -3.53 -3.05 -2.87 -2.58 -2.8 -2.26 -2.36 -1.48 -1.5 -1.64 -1.78 -1.91 -1.49 -1.49 -1.33 -1.04 -1.47 -0.71 -0.61 -0.51 -0.5 -0.42 -0.34 -0.23 -1.81 -19.3 -29 -17.5 -17.7 - - - - -

ROE %

894.29 844.06 786.98 -290.71 -130.56 -77.30 -125.47 -123.99 -143.65 -150.17 -191.59 -168.33 -137.28 -108.03 -81.35 -70.82 -47.85 -45.66 -48.29 -49.95 -63.60 -61.45 -51.97 -43.66 -36.17 -29.48 -28.79 -25.93 -22.55 -20.67 -21.66 -25.67 -28.07 -30.31 -27.66 -23.85 -23.17 -19.61 -18.03 -16.45 -10.67 -9.92 -11.26 -11.83 -14.54 -16.70 4.77 17.85 29.05 16.14 9.04 8.19 - - - - -

ROA %

-48.88 -39.06 -53.27 -49.66 -32.00 -20.95 -35.66 -46.32 -62.97 -65.70 -81.88 -67.17 -83.79 -71.48 -56.59 -51.34 -35.93 -34.73 -36.44 -37.44 -47.57 -45.71 -39.43 -33.98 -29.16 -24.77 -24.30 -21.96 -19.18 -17.66 -17.87 -20.62 -22.15 -23.57 -21.90 -19.29 -19.20 -16.64 -15.43 -14.21 -9.32 -8.75 -8.84 -8.51 -10.27 -11.28 -20.66 -25.21 -29.75 -12.98 -7.27 -6.58 - - - - -

ROCE %

972.21 929.68 866.86 -320.25 -149.71 -89.66 -143.03 -139.84 -155.01 -158.71 -194.96 -159.33 -115.42 -81.87 -55.91 -47.89 -42.78 -41.27 -48.93 -55.58 -60.75 -63.41 -53.80 -45.37 -37.48 -30.34 -29.21 -26.05 -22.34 -20.46 -21.59 -25.79 -28.51 -30.80 -28.24 -24.33 -23.54 -19.88 -18.11 -16.50 -13.10 -12.34 -13.70 -14.30 -14.35 -16.45 4.97 18.04 29.06 16.07 9.01 8.25 - - - - -

Current Ratio

0.8 0.9 1.0 1.1 1.3 1.5 1.6 1.8 2.0 1.6 1.4 - 2.2 2.7 2.9 3.1 3.8 4.2 4.2 4.2 4.2 3.9 3.9 3.9 3.9 6.3 6.3 6.3 6.3 6.9 6.9 6.9 6.9 4.5 4.5 4.5 4.5 6.6 6.6 6.6 6.6 8.5 8.5 8.5 8.5 3.1 3.1 3.1 3.1 13.3 13.3 13.3 - - - - -

DSO

- - 0.9 1.4 1.5 - 86.5 7.3 13.4 - 64.3 9.0 14.1 42.6 138.8 1308.1 188.8 - - - - 32.9 36.9 24.7 13.2 - - 36.5 31.2 50.7 - 12.7 30.9 - - - - - - - - - - - - - - - - - - - - - - - -

DIO

552.9 - 338.0 100.3 93.9 - 173.0 118.9 31.5 - - - - - 33.6 94.2 2279.4 - 740.7 628.2 476.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

286.9 - 213.3 78.8 66.8 - 153.7 205.3 366.9 - - 741.2 297.8 - 143.5 177.5 2696.6 - 1495.6 1268.5 2875.3 - 4551.4 6400.1 6453.9 - 56106.2 77479.9 82404.1 - 1067.9 2796.8 - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

552.9 - 338.0 101.7 95.4 - 259.6 126.2 44.9 - 64.3 9.0 14.1 42.6 172.4 1402.3 2468.3 - 740.7 628.2 476.2 32.9 36.9 24.7 13.2 - - 36.5 31.2 50.7 - 12.7 30.9 - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

266.1 - 124.7 22.9 28.5 - 105.8 -79.1 -322.0 - 64.3 -732.2 -283.7 42.6 28.9 1224.8 -228.3 - -754.9 -640.3 -2399.2 32.9 -4514.5 -6375.4 -6440.8 - -56106.2 -77443.5 -82372.9 50.7 -1067.9 -2784.2 30.9 - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company bluebird bio, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 13.07 1.32 % $ 10.9 B indiaIndia
Replimune Group Replimune Group
REPL
$ 10.86 3.16 % $ 1.01 B usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 45.97 0.92 % $ 827 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Geron Corporation Geron Corporation
GERN
$ 1.17 3.36 % $ 780 M usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.79 2.87 % $ 14.3 M usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 156.19 2.49 % $ 194 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
$ 14.05 0.79 % $ 12.1 B chinaChina
Entera Bio Ltd. Entera Bio Ltd.
ENTX
$ 2.68 10.8 % $ 124 M israelIsrael
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 64.25 0.72 % $ 179 M israelIsrael
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 8.68 4.12 % $ 1.23 B britainBritain
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.39 0.03 % $ 3.07 M israelIsrael
Sanofi Sanofi
SNY
$ 40.61 0.79 % $ 49.6 B franceFrance
Spruce Biosciences Spruce Biosciences
SPRB
$ 39.65 6.39 % $ 30.4 M usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.1 0.88 % $ 61.6 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
$ 1.79 0.21 % $ 213 M usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 10.94 8.94 % $ 93 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 5.42 3.75 % $ 377 M usaUSA
Daré Bioscience Daré Bioscience
DARE
$ 0.72 1.51 % $ 8.05 M usaUSA
Savara Savara
SVRA
$ 4.45 0.53 % $ 990 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 0.07 0.15 % $ 47.6 K chinaChina
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 68.07 0.9 % $ 2.84 B usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 1.31 1.01 % $ 112 M usaUSA
Syros Pharmaceuticals Syros Pharmaceuticals
SYRS
- -8.44 % $ 3.4 M usaUSA
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.57 0.07 % $ 11.3 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.36 0.65 % $ 53.3 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 41.5 0.95 % $ 47.5 B israelIsrael
TG Therapeutics TG Therapeutics
TGTX
$ 53.97 3.0 % $ 7.79 B usaUSA
Gossamer Bio Gossamer Bio
GOSS
$ 8.77 0.11 % $ 2 B usaUSA
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 6.04 0.31 % $ 51.4 M usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 11.88 0.41 % $ 1.6 B usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 3.62 6.27 % $ 1.16 B usaUSA
Innoviva Innoviva
INVA
$ 20.78 0.19 % $ 1.4 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 34.56 0.08 % $ 1.66 B israelIsrael
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 533.12 0.27 % $ 23.6 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 0.21 0.4 % $ 9.6 M israelIsrael
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Vericel Corporation Vericel Corporation
VCEL
$ 40.13 0.33 % $ 2.02 B usaUSA
Veracyte Veracyte
VCYT
$ 43.12 1.16 % $ 3.39 B usaUSA
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
$ 3.5 4.72 % $ 566 M usaUSA
Vir Biotechnology Vir Biotechnology
VIR
$ 9.96 0.58 % $ 1.38 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 25.17 7.46 % $ 2.84 B usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
$ 4.04 0.24 % $ 238 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 37.0 0.33 % $ 2.39 B danmarkDanmark
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 3.6 0.79 % $ 38.3 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 19.03 0.92 % $ 1.94 B usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 2.94 8.36 % $ 176 M franceFrance
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.46 0.02 % $ 5.09 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA